Lin DW, Zheng Y, McKenney JK, et al. - Given that among patients with low-risk prostate cancer treated with immediate surgery, adverse pathology (AP) is predicted by the 17-gene Oncotype DX Genomic Prostate Score (GPS) test, researchers assessed the GPS test as a predictor of results in a multicenter active surveillance cohort. From the Canary Prostate Active Surveillance Study participants, who were men enrolled at 8 sites, diagnostic biopsy tissue was collected. AP (Gleason Grade Group [GG] ≥ 3, ≥ pT3a) in men who had radical prostatectomy following initial surveillance was considered as the primary endpoint. Findings revealed that the observed independent link of GPS with AP following initial active surveillance was not statistically significant, and experts identified no link with upgrading in surveillance biopsy. No significantly improved stratification of risk for AP was obtained by adding GPS to a model comprising prostate-specific antigen density and diagnostic GG vs the clinical variables alone.